ANAPTYSBIO, INC
Company Stats
- Market Cap
- $1.5B
- as of Sep 30, 2026
- Shares Outstanding
- 29.1M
- Free Float
- 17.7%
Income Statement
- Revenue
- $234.6M
- Operating Income
- $47.9M
- Net Income
- -$13.2M
- EBITDA
- $48.5M
- Revenue Growth, 3Y
- 183.6%
- FCF Margin, 3Y Avg
- -283.0%
- FCF Margin, Worst Year
- -708.8%
Cash Flow
- Free Cash Flow
- $19.6M
- FCF Yield
- 1.3%
- Owner FCF Yield
- -1.1%
Balance Sheet
- Cash & Equivalents
- $238.2M
Returns & Capital
- Share Repurchases
- $68.6M
- Buyback Yield, 3Y Avg
- 2.7%
- SBC, 3Y Avg
- $34.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $234.6M | $19.6M | 8.4% |
| FY2024 | $91.3M | -$135.7M | -148.7% |
| FY2023 | $17.2M | -$121.6M | -708.8% |
| FY2022 | $10.3M | -$74.0M | -718.9% |
| FY2021 | $63.2M | -$47.3M | -74.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 11, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges